StockSelector.com
  Research, Select, & Monitor Friday, June 22, 2018 4:59:10 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Gilead Sciences, Inc.$71.07($.45)(.63%)

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  Gilead Sciences, Inc. vs Biotechnology

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.




An exciting industry consisting of companies who develop new drugs to combat such diseases as cancer and other life-threatening diseases. Some may also participate in gene therapy. These firms either bring new drugs to the market themselves (which is a grueling process) or they sell their technology to bigger pharmaceutical companies.
 Totals Company Industry
  Sales: $26,107.0 Mil $93,557.4 Mil
  Market Cap: $94,406.4 Mil $485,757.4 Mil
  Analysts Recommendation: Buy Buy

 Averages Company Industry
 Growth
  Historic Revenue: (14.1%) 42.3%
  Estimated Revenue: (19.4%) 141.1%
  Historic Earnings: (24.7%) (39.3%)
  Estimated Earnings: (13.7%) 9.4%
  Stock Price (1 Year): 6.0% 70.8%
  Cash per Share: (7.0%) 18.7%
  Dividend: N/A N/A
 Price
  Trailing PE: N/A N/A
  Forward PE: 11.5 27.0
  Price-to-Sales: 3.8 N/A
  Price-to-Book: 4.6 4.3
  Dividend Yield: N/A N/A
  Market Cap: $94,406.4 Mil $10,559.9 Mil
  Operations
  Net Margin: 41.2% (2,232.3%)
  Gross Margin: 83.3% 75.5%
  Return on Equity: .2 (.3)
  Return on Assets: .1 (.3)
  Balance Sheet
  Current Ratio: 2.7 4.9
  Quick Ratio: 2.7 4.6
  Cash Ratio: 2.2 3.9
  Debt-to-Equity: 2.4 1.0
  Interest Coverage: .5 1.7
 Technicals
  Relative-Strength Index: 65.7 46.1

 Other companies in Biotechnology Price Market Cap
  Amgen, Inc.  (AMGN) $185.99 $132,238.9 Mil
  Biogen Inc.  (BIIB) $297.34 $62,946.9 Mil
  Celgene Corp.  (CELG) $79.14 $60,803.3 Mil
  Regeneron Pharmaceuticals Inc.  (REGN) $329.04 $37,808.7 Mil
  Incyte Corp.  (INCY) $72.49 $15,344.8 Mil






Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2018 StockSelector.com. All rights reserved.